# ExteNET (NCT00878709)

> Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00878709
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Puma Biotechnology, Inc.
- Conditions: Breast Cancer
- Interventions: neratinib; placebo
- Enrollment: 2840
- Primary outcome: Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2
- Primary outcome: Kaplan-Meier Estimates of Invasive Disease-free Survival (iDFS) at Year 2 by Treatment Arms

## Commentary we found

- YouTube: 23
- Podcasts: 13
- X threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=extenet-nct00878709

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT00878709", "email": "<work email>"}; the inbox owner confirms by the emailed link.